Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice

Mutations in the Leucine Rich Repeat Kinase 2 (LRRK2) gene, first described in 2004 have now emerged as the most important genetic finding in both autosomal dominant and sporadic Parkinson's disease (PD). While a formidable research effort has ensued since the initial gene discovery, little is...

Full description

Bibliographic Details
Main Authors: H.L. Melrose, J.C. Dächsel, B. Behrouz, S.J. Lincoln, M. Yue, K.M. Hinkle, C.B. Kent, E. Korvatska, J.P. Taylor, L. Witten, Y.-Q. Liang, J.E. Beevers, M. Boules, B.N. Dugger, V.A. Serna, A. Gaukhman, X. Yu, M. Castanedes-Casey, A.T. Braithwaite, S. Ogholikhan, N. Yu, D. Bass, G. Tyndall, G.D. Schellenberg, D.W. Dickson, C. Janus, M.J. Farrer
Format: Article
Language:English
Published: Elsevier 2010-12-01
Series:Neurobiology of Disease
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S0969996110002342
id doaj-826034551a614ddaa028378afe1807f9
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author H.L. Melrose
J.C. Dächsel
B. Behrouz
S.J. Lincoln
M. Yue
K.M. Hinkle
C.B. Kent
E. Korvatska
J.P. Taylor
L. Witten
Y.-Q. Liang
J.E. Beevers
M. Boules
B.N. Dugger
V.A. Serna
A. Gaukhman
X. Yu
M. Castanedes-Casey
A.T. Braithwaite
S. Ogholikhan
N. Yu
D. Bass
G. Tyndall
G.D. Schellenberg
D.W. Dickson
C. Janus
M.J. Farrer
spellingShingle H.L. Melrose
J.C. Dächsel
B. Behrouz
S.J. Lincoln
M. Yue
K.M. Hinkle
C.B. Kent
E. Korvatska
J.P. Taylor
L. Witten
Y.-Q. Liang
J.E. Beevers
M. Boules
B.N. Dugger
V.A. Serna
A. Gaukhman
X. Yu
M. Castanedes-Casey
A.T. Braithwaite
S. Ogholikhan
N. Yu
D. Bass
G. Tyndall
G.D. Schellenberg
D.W. Dickson
C. Janus
M.J. Farrer
Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice
Neurobiology of Disease
Parkinson's disease
Transgenic
Dopamine
Microdialysis
Neuropathology
Anxiety
author_facet H.L. Melrose
J.C. Dächsel
B. Behrouz
S.J. Lincoln
M. Yue
K.M. Hinkle
C.B. Kent
E. Korvatska
J.P. Taylor
L. Witten
Y.-Q. Liang
J.E. Beevers
M. Boules
B.N. Dugger
V.A. Serna
A. Gaukhman
X. Yu
M. Castanedes-Casey
A.T. Braithwaite
S. Ogholikhan
N. Yu
D. Bass
G. Tyndall
G.D. Schellenberg
D.W. Dickson
C. Janus
M.J. Farrer
author_sort H.L. Melrose
title Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice
title_short Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice
title_full Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice
title_fullStr Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice
title_full_unstemmed Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice
title_sort impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human lrrk2 transgenic mice
publisher Elsevier
series Neurobiology of Disease
issn 1095-953X
publishDate 2010-12-01
description Mutations in the Leucine Rich Repeat Kinase 2 (LRRK2) gene, first described in 2004 have now emerged as the most important genetic finding in both autosomal dominant and sporadic Parkinson's disease (PD). While a formidable research effort has ensued since the initial gene discovery, little is known of either the normal or the pathological role of LRRK2. We have created lines of mice that express human wild-type (hWT) or G2019S Lrrk2 via bacterial artificial chromosome (BAC) transgenesis. In vivo analysis of the dopaminergic system revealed abnormal dopamine neurotransmission in both hWT and G2019S transgenic mice evidenced by a decrease in extra-cellular dopamine levels, which was detected without pharmacological manipulation. Immunopathological analysis revealed changes in localization and increased phosphorylation of microtubule binding protein tau in G2019S mice. Quantitative biochemical analysis confirmed the presence of differential phospho-tau species in G2019S mice but surprisingly, upon dephosphorylation the tau isoform banding pattern in G2019S mice remained altered. This suggests that other post-translational modifications of tau occur in G2019S mice. We hypothesize that Lrrk2 may impact on tau processing which subsequently leads to increased phosphorylation. Our models will be useful for further understanding of the mechanistic actions of LRRK2 and future therapeutic screening.
topic Parkinson's disease
Transgenic
Dopamine
Microdialysis
Neuropathology
Anxiety
url http://www.sciencedirect.com/science/article/pii/S0969996110002342
work_keys_str_mv AT hlmelrose impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice
AT jcdachsel impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice
AT bbehrouz impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice
AT sjlincoln impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice
AT myue impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice
AT kmhinkle impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice
AT cbkent impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice
AT ekorvatska impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice
AT jptaylor impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice
AT lwitten impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice
AT yqliang impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice
AT jebeevers impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice
AT mboules impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice
AT bndugger impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice
AT vaserna impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice
AT agaukhman impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice
AT xyu impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice
AT mcastanedescasey impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice
AT atbraithwaite impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice
AT sogholikhan impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice
AT nyu impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice
AT dbass impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice
AT gtyndall impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice
AT gdschellenberg impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice
AT dwdickson impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice
AT cjanus impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice
AT mjfarrer impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice
_version_ 1724208706539749376
spelling doaj-826034551a614ddaa028378afe1807f92021-03-22T12:35:43ZengElsevierNeurobiology of Disease1095-953X2010-12-01403503517Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic miceH.L. Melrose0J.C. Dächsel1B. Behrouz2S.J. Lincoln3M. Yue4K.M. Hinkle5C.B. Kent6E. Korvatska7J.P. Taylor8L. Witten9Y.-Q. Liang10J.E. Beevers11M. Boules12B.N. Dugger13V.A. Serna14A. Gaukhman15X. Yu16M. Castanedes-Casey17A.T. Braithwaite18S. Ogholikhan19N. Yu20D. Bass21G. Tyndall22G.D. Schellenberg23D.W. Dickson24C. Janus25M.J. Farrer26Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA; Corresponding authors. Laboratories of Neurogenetics, Mayo Clinic, Department of Neuroscience, 4500 San Pablo Road, Jacksonville, FL 32224, USA. Fax: +1 904 953 7370.Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USADepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USADepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USADepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USADepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USADepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USAVeteran Affairs Medical Center, University of Washington, 1660 S. Columbian Way, Seattle, WA 98108, USADepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USAH. Lundbeck A/S, Ottiliavej 9, Copenhagen, DK-2500, DenmarkDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USADepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USADepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USADepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USADepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USADepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USADepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USADepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USADepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USADepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USADepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USADepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USADepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USAPathology and Laboratory Medicine, University of Pennsylvania School of Medicine, 422 Curie Boulevard, Philadelphia, PA 19104, USADepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USADepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USADepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA; Corresponding authors. Laboratories of Neurogenetics, Mayo Clinic, Department of Neuroscience, 4500 San Pablo Road, Jacksonville, FL 32224, USA. Fax: +1 904 953 7370.Mutations in the Leucine Rich Repeat Kinase 2 (LRRK2) gene, first described in 2004 have now emerged as the most important genetic finding in both autosomal dominant and sporadic Parkinson's disease (PD). While a formidable research effort has ensued since the initial gene discovery, little is known of either the normal or the pathological role of LRRK2. We have created lines of mice that express human wild-type (hWT) or G2019S Lrrk2 via bacterial artificial chromosome (BAC) transgenesis. In vivo analysis of the dopaminergic system revealed abnormal dopamine neurotransmission in both hWT and G2019S transgenic mice evidenced by a decrease in extra-cellular dopamine levels, which was detected without pharmacological manipulation. Immunopathological analysis revealed changes in localization and increased phosphorylation of microtubule binding protein tau in G2019S mice. Quantitative biochemical analysis confirmed the presence of differential phospho-tau species in G2019S mice but surprisingly, upon dephosphorylation the tau isoform banding pattern in G2019S mice remained altered. This suggests that other post-translational modifications of tau occur in G2019S mice. We hypothesize that Lrrk2 may impact on tau processing which subsequently leads to increased phosphorylation. Our models will be useful for further understanding of the mechanistic actions of LRRK2 and future therapeutic screening.http://www.sciencedirect.com/science/article/pii/S0969996110002342Parkinson's diseaseTransgenicDopamineMicrodialysisNeuropathologyAnxiety